Chronic postsurgical pain in Europe: An observational study.
Details
Serval ID
serval:BIB_48E2BE3D7237
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Chronic postsurgical pain in Europe: An observational study.
Journal
European Journal of Anaesthesiology
Working group(s)
euCPSP group for the Clinical Trial Network group of the European Society of Anaesthesiology
Contributor(s)
Lavand'-homme P., Vercauteren M., Fletcher D., Kranke P., Meissner W., Pogatzki-Zahn E., Iohom G., Cinnella G., Aurilio C., Belii A., Filipescu D., Tanase NV., Stamer U., Rehberg- Klug B., Decostered I., Suter MR., Perruchoud C., Blumenthal S., Puig M., Garcia-Filoso A., Brandner B., Varvinskiy AM., Lisnyy I., Kuchyn I.
ISSN
1365-2346 (Electronic)
ISSN-L
0265-0215
Publication state
Published
Issued date
2015
Peer-reviewed
Oui
Volume
32
Number
10
Pages
725-734
Language
english
Notes
Publication types: Journal Article ; Multicenter Study ; Observational Study ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Publication Status: ppublish
Abstract
BACKGROUND: Chronic postsurgical pain (CPSP) is an important clinical problem. Prospective studies of the incidence, characteristics and risk factors of CPSP are needed.
OBJECTIVES: The objective of this study is to evaluate the incidence and risk factors of CPSP.
DESIGN: A multicentre, prospective, observational trial.
SETTING: Twenty-one hospitals in 11 European countries.
PATIENTS: Three thousand one hundred and twenty patients undergoing surgery and enrolled in the European registry PAIN OUT.
MAIN OUTCOME MEASURES: Pain-related outcome was evaluated on the first postoperative day (D1) using a standardised pain outcome questionnaire. Review at 6 and 12 months via e-mail or telephonic interview used the Brief Pain Inventory (BPI) and the DN4 (Douleur Neuropathique four questions). Primary endpoint was the incidence of moderate to severe CPSP (numeric rating scale, NRS ≥3/10) at 12 months.
RESULTS: For 1044 and 889 patients, complete data were available at 6 and 12 months. At 12 months, the incidence of moderate to severe CPSP was 11.8% (95% CI 9.7 to 13.9) and of severe pain (NRS ≥6) 2.2% (95% CI 1.2 to 3.3). Signs of neuropathic pain were recorded in 35.4% (95% CI 23.9 to 48.3) and 57.1% (95% CI 30.7 to 83.4) of patients with moderate and severe CPSP, respectively. Functional impairment (BPI) at 6 and 12 months increased with the severity of CPSP (P < 0.01) and presence of neuropathic characteristics (P < 0.001). Multivariate analysis identified orthopaedic surgery, preoperative chronic pain and percentage of time in severe pain on D1 as risk factors. A 10% increase in percentage of time in severe pain was associated with a 30% increase of CPSP incidence at 12 months.
CONCLUSION: The collection of data on CPSP was feasible within the European registry PAIN OUT. The incidence of moderate to severe CPSP at 12 months was 11.8%. Functional impairment was associated with CPSP severity and neuropathic characteristics. Risk factors for CPSP in the present study were chronic preoperative pain, orthopaedic surgery and percentage of time in severe pain on D1.
TRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT01467102.
OBJECTIVES: The objective of this study is to evaluate the incidence and risk factors of CPSP.
DESIGN: A multicentre, prospective, observational trial.
SETTING: Twenty-one hospitals in 11 European countries.
PATIENTS: Three thousand one hundred and twenty patients undergoing surgery and enrolled in the European registry PAIN OUT.
MAIN OUTCOME MEASURES: Pain-related outcome was evaluated on the first postoperative day (D1) using a standardised pain outcome questionnaire. Review at 6 and 12 months via e-mail or telephonic interview used the Brief Pain Inventory (BPI) and the DN4 (Douleur Neuropathique four questions). Primary endpoint was the incidence of moderate to severe CPSP (numeric rating scale, NRS ≥3/10) at 12 months.
RESULTS: For 1044 and 889 patients, complete data were available at 6 and 12 months. At 12 months, the incidence of moderate to severe CPSP was 11.8% (95% CI 9.7 to 13.9) and of severe pain (NRS ≥6) 2.2% (95% CI 1.2 to 3.3). Signs of neuropathic pain were recorded in 35.4% (95% CI 23.9 to 48.3) and 57.1% (95% CI 30.7 to 83.4) of patients with moderate and severe CPSP, respectively. Functional impairment (BPI) at 6 and 12 months increased with the severity of CPSP (P < 0.01) and presence of neuropathic characteristics (P < 0.001). Multivariate analysis identified orthopaedic surgery, preoperative chronic pain and percentage of time in severe pain on D1 as risk factors. A 10% increase in percentage of time in severe pain was associated with a 30% increase of CPSP incidence at 12 months.
CONCLUSION: The collection of data on CPSP was feasible within the European registry PAIN OUT. The incidence of moderate to severe CPSP at 12 months was 11.8%. Functional impairment was associated with CPSP severity and neuropathic characteristics. Risk factors for CPSP in the present study were chronic preoperative pain, orthopaedic surgery and percentage of time in severe pain on D1.
TRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT01467102.
Keywords
Adult, Aged, Chronic Pain/epidemiology, Chronic Pain/etiology, Europe, Female, Humans, Incidence, Male, Middle Aged, Multivariate Analysis, Neuralgia/epidemiology, Neuralgia/etiology, Pain Measurement, Pain, Postoperative/epidemiology, Prospective Studies, Risk Factors, Surveys and Questionnaires, Time Factors
Pubmed
Web of science
Create date
22/12/2015 18:44
Last modification date
20/08/2019 14:56
Usage data
